Bispecific T Cell Engager for Selective T Cell Malignancy Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bispecific antibodies targeting CD3 antigen for T cell malignancies risk causing immunodeficiency due to binding to both normal and tumor T cells, leading to inadequate therapeutic effects and potential severe side effects.
Innovation Solution
A bispecific antigen-binding molecule that selectively targets tumor-specific antigens on T cell tumor cells while sparing normal T cells by binding to distinct subtypes of antigens expressed on normal T cells, activating them to induce cytotoxicity against tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bispecific antibodies target CD3 antigen for T cell malignancies, then therapeutic effect is improved, but immunodeficiency occurs due to binding to both normal and tumor T cells
Solution Approach 1:
The patent applies local quality by designing a bispecific antibody where one arm targets a pan-T cell antigen (CD3) and the other arm targets a specific T cell malignancy antigen (e.g., CD7, CD5). This creates localized specificity: the antibody exerts its cytotoxic effect primarily on tumor cells expressing both antigens, while normal T cells expressing only CD3 are spared from excessive activation. The differential antigen expression patterns between normal and malignant T cells enable selective therapy.
Solution Approach 2:
The patent employs parameter changes by modifying the antigen-binding specificity parameters of the bispecific antibody. Instead of using two identical or similar antigens, the invention combines CD3 with another T cell-specific antigen that has differential expression levels between normal and malignant T cells. This parameter modification (changing from uniform to differential antigen targeting) allows the antibody to distinguish between normal and tumor cells, reducing immunodeficiency while maintaining therapeutic efficacy.
2Reliability
If bispecific antibodies bind to both normal and tumor T cells, then therapeutic coverage is improved, but side effects increase due to normal T cell depletion
Solution Approach 1:
The patent applies segmentation by dividing the T cell population into two groups based on their antigen expression profiles: normal T cells (expressing CD3 but low or absent expression of the second target antigen) and malignant T cells (expressing both CD3 and the second target antigen at high levels). The bispecific antibody is designed to preferentially bind and activate against the segmented malignant population, thereby achieving therapeutic coverage while minimizing harm to normal T cells.
Solution Approach 2:
The patent utilizes partial action by focusing the cytotoxic effect primarily on tumor cells rather than attempting to eliminate all T cells expressing CD3. By requiring dual antigen binding (CD3 plus another T cell-specific antigen), the antibody achieves sufficient therapeutic coverage against malignant cells without excessively depleting the normal T cell population, thus reducing side effects while maintaining adequate therapeutic impact.
3Power
If CD3 is used as target antigen, then T cell activation is improved, but discrimination between normal and malignant cells is lost
Solution Approach 1:
The patent applies merging by combining two antigen-targeting functions into a single bispecific antibody molecule: CD3 binding (for T cell activation) and binding to a second T cell-specific antigen (for cell discrimination). This merged structure enables the antibody to simultaneously achieve strong T cell activation through CD3 engagement while discriminating between normal and malignant cells through the second antigen's differential expression pattern.
Solution Approach 2:
The patent introduces a second T cell-specific antigen as an intermediary marker that mediates discrimination between normal and malignant T cells. While CD3 serves as the primary activation trigger, the second antigen (such as CD7, CD5, or other T cell markers with differential expression) acts as an intermediary that provides the necessary specificity to distinguish tumor cells from normal T cells, enabling selective targeting without compromising activation power.
Data Source
AI summary
A therapeutic agent for a T cell malignancy includes a bispecific antigen-binding molecule including (1) at least one portion that specifically binds to a target tumor antigen expressed on T cell tumor cells, and (2) at least one portion that specifically binds to a normal T cell-side target antigen having subtypes, provided that the target tumor antigen expressed on the T cell tumor cells is either not present on normal T cells, or if present, the normal T cells are not substantially activated when the bispecific antigen-binding molecule binds to the same antigen as the target tumor antigen present on the normal T cells, but binding of the bispecific antigen-binding molecule to the normal T cell-side target antigen activates the normal T cells, and a sufficient proportion of a subtype of the normal T cell-side target antigen is present to provide a sufficient number of activated T cells for the treatment.